Skip to main content
Erschienen in:

08.11.2024 | CME

Update Vorhofflimmern bei geriatrischen Patienten

verfasst von: Dr. med. univ. M. Gosch, B. Habboub, J. N. Krohn, M. Pauschinger, T. Deneke

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 8/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vorhofflimmern ist die häufigste Herzrhythmusstörung im Alter. Als Folge der positiven Daten zur Katheterablation hat sich der Fokus in der symptomatischen Therapie auf die Rhythmuskontrolle gelegt. Auch ältere Patienten können von einer Katheterablation profitieren. Die orale Antikoagulation bleibt wesentlicher Bestandteil der pharmakologischen Therapie beim Vorhofflimmern. Neue Studienergebnisse belegen, dass geriatrische Patienten eines individuellen Behandlungsansatzes bedürfen; dieser sollte auf den Empfehlungen der aktuellen Leitlinien und einschließlich dem Einsatz ergänzender Hilfsmittel basieren. Die Beurteilung der Funktionalität sollte in der Therapie und der Therapiezielplanung Berücksichtigung finden ebenso wie die mit dem Vorhofflimmern assoziierten Beschwerden. Zur Rhythmuskontrolle stehen akut die Kardioversion und langfristig eine medikamentöse oder interventionelle (Katheterablation) rhythmusstabilisierende Therapie zur Verfügung.
Literatur
1.
Zurück zum Zitat Arnold AM, Psaty BM, Kuller LH, Burke GL, Manolio TA, Fried LP et al (2005) Incidence of cardiovascular disease in older Americans: the cardiovascular health study. J Am Geriatr Soc 53(2):211–218CrossRefPubMed Arnold AM, Psaty BM, Kuller LH, Burke GL, Manolio TA, Fried LP et al (2005) Incidence of cardiovascular disease in older Americans: the cardiovascular health study. J Am Geriatr Soc 53(2):211–218CrossRefPubMed
2.
Zurück zum Zitat Lowres N, Neubeck L, Redfern J, Freedman SB (2013) Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 110(2):213–222CrossRefPubMed Lowres N, Neubeck L, Redfern J, Freedman SB (2013) Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 110(2):213–222CrossRefPubMed
3.
Zurück zum Zitat Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S et al (2005) A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 9(40):1–74CrossRef Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S et al (2005) A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 9(40):1–74CrossRef
4.
Zurück zum Zitat Gotze M, Ebelt H (2024) Prevalence, incidence and predictive factors of atrial fibrillation in geriatric patients—A prospective observational study. Z Gerontol Geriatr 57(2):120–125PubMed Gotze M, Ebelt H (2024) Prevalence, incidence and predictive factors of atrial fibrillation in geriatric patients—A prospective observational study. Z Gerontol Geriatr 57(2):120–125PubMed
5.
Zurück zum Zitat Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, filipppatos G, Kalman JM, La Meir M. (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 00:1–125 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, filipppatos G, Kalman JM, La Meir M. (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 00:1–125
6.
Zurück zum Zitat Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147CrossRefPubMed Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147CrossRefPubMed
7.
Zurück zum Zitat Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418CrossRefPubMedPubMedCentral Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Chung SC, Lai A, Lip GYH, Lambiase PD, Providencia R (2023) Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. Europace 25(2):351–359CrossRefPubMed Chung SC, Lai A, Lip GYH, Lambiase PD, Providencia R (2023) Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. Europace 25(2):351–359CrossRefPubMed
9.
Zurück zum Zitat Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J et al (2021) Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 384(4):305–315CrossRefPubMed Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J et al (2021) Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 384(4):305–315CrossRefPubMed
10.
Zurück zum Zitat Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383(14):1305–1316CrossRefPubMed Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383(14):1305–1316CrossRefPubMed
11.
Zurück zum Zitat Rillig A, Borof K, Breithardt G, Camm AJ, Crijns H, Goette A et al (2022) Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation 146(11):836–847CrossRefPubMed Rillig A, Borof K, Breithardt G, Camm AJ, Crijns H, Goette A et al (2022) Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation 146(11):836–847CrossRefPubMed
12.
Zurück zum Zitat Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A et al (2022) Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation 145(23):1693–1704CrossRefPubMed Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A et al (2022) Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation 145(23):1693–1704CrossRefPubMed
13.
Zurück zum Zitat Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D et al (2023) Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial. JAMA 330(10):925–933CrossRefPubMedPubMedCentral Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D et al (2023) Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial. JAMA 330(10):925–933CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Boehmer AA, Rothe M, Zezyk C, Soether CM, Dobre BC, Kaess BM et al (2022) Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation. J Clin Med 11(20) Boehmer AA, Rothe M, Zezyk C, Soether CM, Dobre BC, Kaess BM et al (2022) Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation. J Clin Med 11(20)
15.
Zurück zum Zitat Oates CP, Basyal B, Whang W, Reddy VY, Koruth JS (2024) Trends in safety of catheter-based electrophysiology procedures in the last 2 decades: A meta-analysis. Heart Rhythm Oates CP, Basyal B, Whang W, Reddy VY, Koruth JS (2024) Trends in safety of catheter-based electrophysiology procedures in the last 2 decades: A meta-analysis. Heart Rhythm
16.
Zurück zum Zitat Kautzner J, Peichl P, Sramko M, Cihak R, Aldhoon B, Wichterle D (2017) Catheter ablation of atrial fibrillation in elderly population. J Geriatr Cardiol 14(9):563–568PubMedPubMedCentral Kautzner J, Peichl P, Sramko M, Cihak R, Aldhoon B, Wichterle D (2017) Catheter ablation of atrial fibrillation in elderly population. J Geriatr Cardiol 14(9):563–568PubMedPubMedCentral
17.
Zurück zum Zitat Catanzaro JN, Assis FR, Verma A, Tandri H, Tilz RR, Spragg DD et al (2024) Recognition, Management, and Prevention of Atrioesophageal Fistula. JACC Clin Electrophysiol 10(6):1232–1241CrossRefPubMed Catanzaro JN, Assis FR, Verma A, Tandri H, Tilz RR, Spragg DD et al (2024) Recognition, Management, and Prevention of Atrioesophageal Fistula. JACC Clin Electrophysiol 10(6):1232–1241CrossRefPubMed
18.
Zurück zum Zitat Tilz RR, Schmidt V, Purerfellner H, Maury P, Chun K, Martinek M et al (2023) A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J 44(27):2458–2469CrossRefPubMedPubMedCentral Tilz RR, Schmidt V, Purerfellner H, Maury P, Chun K, Martinek M et al (2023) A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J 44(27):2458–2469CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A et al (2022) Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace 24(8):1256–1266CrossRefPubMedPubMedCentral Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A et al (2022) Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace 24(8):1256–1266CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H et al (2012) Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98(3):195–201CrossRefPubMed Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H et al (2012) Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98(3):195–201CrossRefPubMed
21.
Zurück zum Zitat Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E et al (2021) AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 42(46):4731–4739CrossRefPubMed Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E et al (2021) AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 42(46):4731–4739CrossRefPubMed
22.
Zurück zum Zitat Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696CrossRefPubMed Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696CrossRefPubMed
23.
Zurück zum Zitat Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307CrossRefPubMed Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307CrossRefPubMed
24.
Zurück zum Zitat Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159(7):677–685CrossRefPubMed Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159(7):677–685CrossRefPubMed
25.
Zurück zum Zitat Donze J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125(11):1095–1102CrossRefPubMed Donze J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125(11):1095–1102CrossRefPubMed
26.
Zurück zum Zitat Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189CrossRefPubMedPubMedCentral Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Joosten LPT, van Doorn S, van de Ven PM, Kohlen BTG, Nierman MC, Koek HL et al (2024) Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation 149(4):279–289PubMed Joosten LPT, van Doorn S, van de Ven PM, Kohlen BTG, Nierman MC, Koek HL et al (2024) Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation 149(4):279–289PubMed
28.
Zurück zum Zitat Binding C, Blanche P, Lip GYH, Kamper AL, Lee CJY, Staerk L et al (2024) Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 10(3):210–218CrossRefPubMed Binding C, Blanche P, Lip GYH, Kamper AL, Lee CJY, Staerk L et al (2024) Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother 10(3):210–218CrossRefPubMed
29.
Zurück zum Zitat Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N et al (2023) Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med 389(13):1167–1179CrossRefPubMed Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N et al (2023) Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med 389(13):1167–1179CrossRefPubMed
30.
Zurück zum Zitat Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF et al (2024) Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med 390(2):107–117CrossRefPubMed Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF et al (2024) Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med 390(2):107–117CrossRefPubMed
31.
Zurück zum Zitat Zimerman A, Braunwald E, Steffel J, Van Mieghem NM, Palazzolo MG, Murphy SA et al (2024) Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol Zimerman A, Braunwald E, Steffel J, Van Mieghem NM, Palazzolo MG, Murphy SA et al (2024) Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol
32.
Zurück zum Zitat Pilotto ANV, Polidori MC, Strandberg T, Topinkova E, Cruz-Jentoft AJ, Custodero C, Barbagallo M, Maggi S (2023) the EUROSAF Study Investigators Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study. Age Ageing 52(11) Pilotto ANV, Polidori MC, Strandberg T, Topinkova E, Cruz-Jentoft AJ, Custodero C, Barbagallo M, Maggi S (2023) the EUROSAF Study Investigators Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study. Age Ageing 52(11)
33.
Zurück zum Zitat Gloekler S, Saw J, Koskinas KC, Kleinecke C, Jung W, Nietlispach F et al (2017) Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. Int J Cardiol 249:234–246CrossRefPubMed Gloekler S, Saw J, Koskinas KC, Kleinecke C, Jung W, Nietlispach F et al (2017) Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. Int J Cardiol 249:234–246CrossRefPubMed
Metadaten
Titel
Update Vorhofflimmern bei geriatrischen Patienten
verfasst von
Dr. med. univ. M. Gosch
B. Habboub
J. N. Krohn
M. Pauschinger
T. Deneke
Publikationsdatum
08.11.2024
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 8/2024
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-024-02375-4